News Column

Researchers from Mayo Clinic Detail Findings in Measles (High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted...

July 30, 2014



Researchers from Mayo Clinic Detail Findings in Measles (High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Morbillivirus Infections have been published. According to news originating from Rochester, Minnesota, by NewsRx correspondents, research stated, "The relationship between ligand-receptor affinity and antitumor potency of an oncolytic virus was investigated using a panel of six HER2/neu (HER2)-targeted measles viruses (MVs) displaying single-chain antibodies (scFv) that bind to the same epitope on HER2, but with affinities ranging from 10(-6) to 10(-11) M. All viruses were able to infect SKOV3ip.1 human ovarian cancer cells in vitro; but only the high-affinity MV (Kd >= 10(-8) M) induced cytopathic effects of syncytia formation in the cell monolayers."

Our news journalists obtained a quote from the research from Mayo Clinic, "In contrast, all six viruses were therapeutically active in vivo against orthotopic human ovarian SKOV3ip.1 tumor xenografts in athymic mice compared with saline-treated controls. The oncolytic activities of MV displaying the high-affinity scFv (Kd = 10(-9), 10(-10), 10(-11) M) were not significantly superior to MV displaying scFv with Kd of 10(-8) M or less."

According to the news editors, the research concluded: "Results from this study suggest that increasing the receptor affinity of the attachment protein of an oncolytic MV has minimal impact on its in vivo efficacy against a tumor that expresses the targeted receptor."

For more information on this research see: High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Therapy, 2014;21(6):256-260. Cancer Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Cancer Gene Therapy - www.nature.com/cgt/)

The news correspondents report that additional information may be obtained from L. Suksanpaisan, Mayo Clinic, Dept. of Obstet & Gynecol, Rochester, MN 55905, United States. Additional authors for this research include S.J. Russel and K.W. Peng (see also Morbillivirus Infections).

Keywords for this news article include: Rochester, Minnesota, United States, North and Central America, Measles, Morbillivirus Infections, Paramyxoviridae Infections, RNA Viruses, Therapy

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters